A recent study published in the Journal of Pharmacology and Experimental Therapeutics highlights the potential of the marijuana compound THC in managing pain associated with sickle cell disease.
The study, titled “Δ9-Tetrahydrocannabinol Alleviates Hyperalgesia in a Humanized Mouse Model of Sickle Cell Disease,” was published online ahead of print by the US National Library of Medicine.
Sickle cell disease (SCD) is characterized by chronic pain and unpredictable episodes of acute pain, severely affecting patients’ quality of life and life expectancy. Traditional pain management for SCD relies heavily on opioid analgesics, which often have limited efficacy and significant adverse effects. Researchers note that “Cannabis has emerged as a potential alternative, yet its efficacy remains uncertain.”
Continue reading